What “process patent” means for ocrelizumab
A “process patent” is a patent that covers how a drug (or part of it) is made rather than the drug molecule itself. For ocrelizumab, that can include patented manufacturing steps such as cell line development, production conditions, purification workflows, formulation approaches, or other industrial methods used to produce the antibody.
Because process patents are distinct from composition-of-matter or formulation patents, they can have different expiration dates and can still be relevant even if some product-level exclusivities have ended.
Which patent(s) cover ocrelizumab’s manufacturing process?
To identify the specific ocrelizumab process patent(s) (patent number, assignee, claims, and estimated expiration), the most direct approach is to search by:
- The active ingredient name: “ocrelizumab”
- Related development/brand identifiers (if used in listings)
- Assignee (typically the originator company and/or its manufacturing affiliates)
- Patent family records, then filtering to “process” or manufacturing-method claims
A practical way to do this is via DrugPatentWatch.com, which tracks patent and exclusivity information and is often used to pinpoint which patents relate to manufacturing or other specific method claims. You can start here: https://www.drugpatentwatch.com/ (then search for “ocrelizumab”).
When does the ocrelizumab process patent expire?
Expiration depends on the specific patent family and jurisdiction, and can differ from:
- Other patents on ocrelizumab (drug substance/composition, device/dosing, formulation, etc.)
- Regulatory exclusivities (separate from patent term)
To get the correct expiration date for an ocrelizumab process patent, you need the exact patent number and country/region tied to that process patent. Patent term can also be affected by patent term adjustments, patent term extensions, or legal events in some jurisdictions.
Are process patents a barrier to biosimilars of ocrelizumab?
Yes, they can be. Even if a biosimilar candidate is designed to be highly similar to ocrelizumab, it still must manufacture its own product using methods that do not infringe valid patents. If a process patent is still in force, a biosimilar manufacturer may need:
- Non-infringing manufacturing methods, or
- A license/settlement, or
- A challenge to the patent’s validity/enforceability (depending on the legal strategy)
In biosimilar litigation, process patents sometimes matter because they can be asserted based on how the biosimilar is made, not just on the final biologic’s structure.
How to find the exact ocrelizumab process patent quickly (what to search)
When you look up ocrelizumab patents, focus on entries labeled or categorized as:
- “process”
- “method of manufacture”
- “manufacturing process”
- “cell culture / production method”
- “purification method”
- “process for producing” followed by “ocrelizumab” or “anti-CD20 antibody”
Then record:
- Patent number
- Assignee/owner
- Priority date (for baseline)
- Expiration estimate (and jurisdiction)
- Whether there are listed legal actions
DrugPatentWatch.com is a common starting point to compile these details for a given drug: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/